Project Description
Dr. Bret A. Witter joined Los Alamitos Cardiovascular in 2003 as a partner. Dr. Witter is board certified in Echocardiography, Cardiovascular Disease and Internal Medicine (1990-2020). During the years 1996-2018, Dr. Bret Witter was an Assistant Clinical Professor at the David Geffen School of Medicine, UCLA.
Dr. Bret A. Witter’s Curriculum Vitae
Specialties
Cardiovascular Diseases and Echocardiography
Board Certifications and Licensure
- Certified Echocardiography
National Board of Echocardiography
2012 - Certified in Cardiovascular Disease
American Board of Internal Medicine
November 1993 (Recertifications: 2003 and 2013) - Certified in Internal Medicine
American Board of Internal Medicine
1990 (Recertifications: 2000 and 2009) - FLEX (Federal Licensing Examination)
Part 1: 1985 | Part 2: 1986 - National Boards (Taken Individually)
1984 – 1987 - NASPE Testamur (Exam)
North American Society of Pacing and Electrophysiology
1998
Languages Spoken
- English
- Medical Spanish
Current Hospital Appointments
Hospital Activities
Los Alamitos Medical Center
- Chairman, Pharmacy and Therapeutics, 2008 – 2014
St. Mary Medical Center
- Vice Chief of Medicine, 2002 – 2003
- Medical Director of Cardiopulmonary Unit, 2003
- Pharmacy and Therapeutics, 2001 – 2002
- Cardiac Catheterization/Cardiac Surgery Committee, 1996 – 2003
- Cardiac Catheterization/Cardiac Surgery Committee,1996 – 2000
- CCU/ICU Committee, 1994
MemorialCare Health System
Community Hospital Long Beach
- Chairman, Cardiac Advisory Board, 1996 – 1998
Professional Societies
- American College of Physicians (FACP)
Fellow: February 2002 - American College of Cardiology (FACC)
Fellow: May 1995 - Los Angeles County Medical Association
Member: 1995 – Present - American College of Cardiology
Member: 1990 – Present - American College of Physicians
Member: 1987 – Present
Academic Appointments
- Assistant Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles (UCLA)
1996 – 2018
Work History
- Los Alamitos Cardiovascular
Los Alamitos, California
October 1993 – Present - Cardiovascular Associates
Long Beach, California
July 1993 – October 1993
Teaching
- Cardiology Conference
St. Mary Medical Center Long Beach
2007 – Present - ICU Morning Report
St. Mary Medical Center Long Beach
1993 – 2003, 2007 – 2009 - CCU/Cardiology Rounds
St. Mary Medical Center Long Beach
1993 – 2003
Professional Recognition
- Special Recognition for Teaching Excellence
St. Mary Medical Center Long Beach
2003 – 2004 - Outstanding Teaching Physician
St. Mary Medical Center Long Beach
2000 – 2001 - Outstanding Teaching Physician
St. Mary Medical Center Long Beach
1993 – 1994
Intramural Presentations
- “Differentiation of Cardiac and non Cardiac chest pain.”
CARDIOLOGY 2000 symposium at Long Beach, California Hyatt,
May 13, 2000 - “Transesophageal Echocardiography in the Critical care Setting.”
CRITICAL CARE TRIAD, St. Mary Medical Center Long Beach,
January 19, 1995
Publications
- Witter BA, Decristofaro D. “Muscle Bands, Tendons and Trabeculations.” (Letter) Am J. Cardiol. 1992; 71:499 – 500.
Education
- Cardiovascular Diseases Fellowship
St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
Long Beach, California
July 1990 – June 1993 - Internal Medicine Residency
St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
Long Beach, California
July 1988 – June 1990 - Internal Medicine Internship
St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
Long Beach, California
July 1987 – June 1988 - Medical Education
Baylor College of Medicine
Houston, Texas
August 1983 – June 1987 - Undergraduate Education
Biological Sciences
University of California, Irvine (UCI)
Irvine, California
September 1979 – June 1983
Education Honors and Awards
- Phi Beta Kappa
Magna Cum Laude
University of California, Irvine 1983
Research Experience
- AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
Sub-Investigator | 2019
Sponsor: CSL Behring LLC
NCT03473223 - COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
Sub-Investigator | 2018 – Present
Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
NCT03196349 - NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
Sub-Investigator | 2019
Sponsor: Milestone Pharmaceuticals Inc.
NCT03464019 - NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
Sub-Investigator | 2019
Sponsor: Milestone Pharmaceuticals Inc.
NCT03635996 - PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
Sub-Investigator | 2018 – Present
Sponsor: Novartis
NCT02924727 - PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
Sub-Investigator | 2018 – Present
Sponsor: Eko Devices - GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
Sub-Investigator | 2017 – Present
Sponsor: Amgen
NCT02929329 - PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Sub-Investigator | 2017 – 2019
Sponsor: Novartis
NCT02887183 - Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
Sub-Investigator | 2016 – Present
Sponsor: CVRx, Inc.
NCT02627196 - MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
Sub-Investigator | 2016 – 2017
Sponsor: Gilead/ICON - THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
Sub-Investigator | 2015 – Present
Sponsor: AstraZeneca
NCT01991795 - Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
Sub-Investigator | 2015 – 2016
Sponsor: Amgen, Evidera - DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
Sub-Investigator | 2013 – 2018
Sponsor: AstraZeneca
NCT01730534 - ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Sub-Investigator | 2013 – 2017
Sponsor: Sanofi
NCT01663402 - SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
Sub-Investigator | 2013 – 2017
Sponsor: Yale University School of Medicine/NIH
NCT01755052 - RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
Sub-Investigator | 2013– 2014
Sponsor: Janssen Scientific Affairs/Johnson & Johnson - Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
Sub-Investigator | 2013
Sponsor: Tasly Pharmaceuticals
NCT0169580 - Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
Sub-Investigator | 2013 – 2018
Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
NCT01594333 - User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
Sub-Investigator | 2012
Sponsor: Alere San Diego - Mission® PT Coagulation Monitoring System Clinical Study.
Principal Investigator | 2012
Sponsor: ACON Laboratories, INC - The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
Sub-Investigator | 2012 – 2015
Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
NCT00786474 - GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
Sub-Investigator | 2012 – Present
Sponsor: Boehringer Ingelheim
NCT01468701 - BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
Sub-Investigator | 2010 – 2012
Sponsor: St. Jude Medical Center
NCT01062126 - The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
Sub-Investigator | 2010 – 2014
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
NCT01174550 - ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Sub-Investigator | 2010 – 2017
Sponsor: Janssen Scientific Affairs, LLC
Collaborator: Duke Clinical Research
NCT01165710 & NCT01701817 - RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
Principal Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00837798 - FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00418314 - SAFE (Silent Atrial Fibrillation Detection with Stored EGMS).
Sponsor: Guidant Corporation - ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
Sub-Investigator | 2009 – 2015
Sponsor: Daiichi Sankyo Pharma Development
NCT00781391 - Fosiniopril Drug Study.
Sub-Investigator | 1992
Sponsor: Bristol- Myers Squibb Company - Supine Bike/Stress Echo (Unpublished).
A.S. Abbasi, MD, FACC
Long Beach, California - Molecular Biology/ Immunology Cell Culture, electrophoresis techniques, 1978 – 1979. Gale Granger, PhD
University of California, Irvine